Published March 19, 2013 | Version v1
Journal article

Progress risk assessment of oral premalignant lesions with saliva miRNA analysis

  • 1. Department of General Dentistry, Ninth People's Hospital, School of Stomatology, Shanghai Jiao Tong University School of Medicine,Shanghai Key Laboratory of Stomatology, 639 Zhi Zao Ju Road, Shanghai, 200011 (China)
  • 2. Department of Stomatology, Tai'an Central Hospital, Tai'an, Shandong, 271000 (China)
  • 3. Department of Oral & Maxillofacial-Head & Neck Oncology, Ninth People's Hospital, School of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, 200011 (China)

Description

Oral cancer develops through multi-stages: from normal to mild (low grade) dysplasia (LGD), moderate dysplasia, and severe (high grade) dysplasia (HGD), to carcinoma in situ (CIS) and finally invasive oral squamous cell carcinomas (OSCC). Clinical and histological assessments are not reliable in predicting which precursor lesions will progress. The aim of this study was to assess the potential of a noninvasive approach to assess progress risk of oral precancerous lesions. We first used microRNA microarray to profile progressing LGD oral premaligant lesions (OPLs) from non-progressing LGD OPLs in order to explore the possible microRNAs deregulated in low grade OPLs which later progressed to HGD or OSCC. We then used RT-qPCR to detect miRNA targets from the microarray results in saliva samples of these patients. We identified a specific miRNA signature that is aberrantly expressed in progressing oral LGD leukoplakias. Similar expression patterns were detected in saliva samples from these patients. These results show promise for using saliva miRNA signature for monitoring of cancer precursor lesions and early detection of disease progression

Availability note (English)

Available from http://dx.doi.org/10.1186/1471-2407-13-129; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637283

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
13
Journal Page Range
p. 129
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46112049
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; CHARGES; HAZARDS; MONITORING; PATIENTS; PRECURSOR; RISK ASSESSMENT; SALIVA
Descriptors DEC
BIOLOGICAL MATERIALS; BODY FLUIDS; DISEASES; MATERIALS; NEOPLASMS

Optional Information

Copyright
Copyright (c) 2013 Yang et al.
Notes
PMCID: PMC3637283; PUBLISHER-ID: 1471-2407-13-129; PMID: 23510112; OAI: oai:pubmedcentral.nih.gov:3637283; licensee BioMed Central Ltd.